TheEdgeResearch
Home / Stocks / SBMFF

Sino Biopharmaceutical Limited (SBMFF)

OTC Healthcare Medical - Pharmaceuticals
$0.69 ▲ +0.00%
Market Cap
$12.38B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.60
52-Wk Range
0.5928-1.09
CEO
S. Y. Tse
Country
HK
Currency
USD

Sino Biopharmaceutical Limited operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Hong Kong, HK. The stock last traded at $0.69, up 0.00% on the session, giving a market capitalisation of $12.38B. On trailing twelve-month figures it carries a trailing P/E of 35.78, a net margin of 7.1%. Its beta of 0.60 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
35.78
Price / Sales
2.52
Price / Book
2.64
EV / EBITDA
8.36
Gross margin
82.4%
Operating margin
29.8%
Net margin
7.1%
Return on equity
—
Debt / equity
0.53
Current ratio
1.63
Dividend yield
2.2%
Payout ratio
62.9%
Company profile
Exchange
Other OTC
Employees
21,435
IPO date
2010-02-22
Headquarters
Hong Kong, HK
About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited is an investment holding company that operates as an integrated pharmaceutical enterprise. It researches, develops, manufactures, and markets a wide range of modernized Chinese medicines and chemical medicines. The company's therapeutic areas of focus include oncology, liver disease, respiratory, and surgery/pain relief, with its primary market being mainland China. [9, 12, 15, 19]

Comparable companies

Sino Biopharmaceutical Limited is most often compared with the following Healthcare names:

AKTXAXLABCDABLRXBVXVCANFDOMHFBIOPGTBPHSTO
More research on SBMFF
SBMFF technical analysis SBMFF TheEdge Score Compare against peers
Open full interactive analysis & DCF →